Table 1.
Sociodemographic characteristics and illness-related data of the participants with MG
| N | % | |
|---|---|---|
| Gender | ||
| female | 31 | 74 |
| male | 11 | 26 |
| Marital status | ||
| married | 30 | 71 |
| single | 8 | 19 |
| divorced/widow | 4 | 10 |
| Educational status | ||
| ≤ 5-year | 6 | 14 |
| 5–8-year | 27 | 64 |
| 9–11-year | 9 | 22 |
| MG duration | ||
| 1 year | 4 | 10 |
| 1–3 years | 14 | 33 |
| > 3 years | 24 | 57 |
| Diagnosis time | ||
| < 1 year | 30 | 71 |
| ≥ 1 year | 12 | 29 |
| Osserman and Genkins Classification* | ||
| Stage I | 6 | 14 |
| Stage IIA | 29 | 69 |
| Stage IIB | 7 | 17 |
| Treatment | ||
| Prednisolone | 23 | 55 |
| Combination$ | 19 | 45 |
*
Osserman and Genkins classification; stageI: ocular; stage IIA: mildly generalized, no crisis; stageIIB: moderately generalized, inadequate treatment response, bulbar involvement, no crisis.
$
prednisolone and azathioprine or pyridostigmine
MG: Myasthenia Gravis.